Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
1 other identifier
observational
550
1 country
1
Brief Summary
Prevalence of participants who have protective immunity to measles virus is less than ninety percent. Predictor of adequate measles antibody levels include the following :
- History of measles infection
- History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)
- History of measles exposure Predictor of inadequate measles antibody levels include the following :
- Born outside Thailand
- History of staying outside Thailand for long time in childhood
- Living in the rural area for a long period in childhood
- Fail to participate school system on time
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2012
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 16, 2012
CompletedFirst Posted
Study publicly available on registry
May 18, 2012
CompletedStudy Start
First participant enrolled
July 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2013
CompletedMay 18, 2012
May 1, 2012
6 months
May 16, 2012
May 17, 2012
Conditions
Keywords
Study Arms (2)
Adequate antimeales antibody levels
ELISA test OD \> 0.1
Inadequate measles antibody levels
ELISA test OD \< 0.1
Eligibility Criteria
Health Thai participant age 18-30 years old.
You may qualify if:
- Age 18-30 years old
You may not qualify if:
- Last measles vaccination less than 10 years of age
- Immunocompromised host including congenital immune defect, splenectomy or splenic dysfunction, history of suspect HIV exposure, taking immunosuppressant
- Receiving blood or blood product within 3 months
- Receiving others vaccinations or immunoglobulins or any medication that possibly decrease immune response
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Queen Saovabha Memorial Institute
Bangkok, Bangkok, 10330, Thailand
Related Links
Biospecimen
Each participant will be taken blood sample approximately 8 ml. The blood sample will be centrifuged and kept as serum. The serum will be kept under - 20 degree Celsius. Then, all serum will be tested by ELISA.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jaruboot Angsanakul, M.D.
Queen Saovabha Memorial Institute
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Jaruboot Angsanakul
Study Record Dates
First Submitted
May 16, 2012
First Posted
May 18, 2012
Study Start
July 1, 2012
Primary Completion
January 1, 2013
Study Completion
March 1, 2013
Last Updated
May 18, 2012
Record last verified: 2012-05